Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
Maxime Fayon, Carolina Martínez-Cingolani, Audrey Abecassis, Nathalie Roders, Elisabeth Nelson, Caroline Choisy, Alexis Talbot, Armand Bensussan, Jean‐Paul Fermand, Bertrand Arnulf, Jean-Christophe Bories
Topics & Concepts
ToxicityMultiple myelomaCD38Cancer researchMedicineInternal medicineBiologyGeneticsStem cellCD34Multiple Myeloma Research and TreatmentsCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies Research